|1.||Zhang, John H: 5 articles (06/2015 - 09/2009)|
|2.||Zhang, Hui: 5 articles (11/2012 - 04/2004)|
|3.||Zhang, Z: 5 articles (07/2001 - 06/2000)|
|4.||Paraskeva, C: 4 articles (10/2007 - 01/2000)|
|5.||McFadden, David W: 4 articles (10/2006 - 05/2004)|
|6.||Jackson, Barbara J: 4 articles (10/2006 - 05/2004)|
|7.||Riggs, Dale R: 4 articles (10/2006 - 05/2004)|
|8.||Drozdowicz, D: 4 articles (06/2001 - 10/2000)|
|9.||Konturek, S J: 4 articles (06/2001 - 10/2000)|
|10.||Brzozowski, T: 4 articles (06/2001 - 10/2000)|
01/01/2012 - "The current study proves that NS398 induces apoptosis in A549 cells, thereby inhibiting tumor growth. "
05/01/2008 - "The aim of our study was to investigate the mechanism of growth inhibitory effect of selective inhibition of COX-2 by NS-398 on human cancer cells. "
01/01/2014 - "We show that inhibition of the COX-2/PGE₂ pathway by treating tumor spheroids with NS-398, a selective COX-2 inhibitor, reverses the TRAIL-resistance and decreases the incidence of a CD44hiCD24lo population. "
09/01/2013 - "Furthermore, addition of the COX-2 inhibitor NS-398 prevented the stimulation of cancer cell invasion induced either by irradiated fibroblasts or IL1β. "
12/01/2012 - "The ability of N2IC to enhance tumor progression in SC-M1 cells was suppressed by knockdown of COX-2 or treatment with NS-398, a COX-2 inhibitor. "
11/01/2009 - "CLP rats showed unrelenting climbs in AST and ALT values; NS-398 rat levels peaked at 6 h and returned to normal after 12 h; the biochemical evidence of protection against septic liver damage was also seen morphologically, with ultrastructural and histologic normalization of nuclear appearances 12 h after sepsis induction with NS-398 pretreatment. "
11/01/2009 - "Six each of CLP and NS-398 animals were sacrificed at 3, 6, 12, and 24 h after induction of sepsis. "
01/01/2004 - "However, it remains unclear if the observed effect of NS-398 treatment is gender-related following hemorrhagic shock and subsequent sepsis. "
01/01/2015 - "We further observed that indomethacin or NS-398 delivery accelerated zebrafish death rates during LPS induced sepsis. "
01/01/2004 - "Despite a significant reduction of PGE(2) concentration, NS-398 treatment has no beneficial effects on cytokine release and survival in this model of hemorrhage and subsequent sepsis."
03/01/2005 - "This study examined whether NS398, a COX-2 inhibitor, inhibited cell proliferation and increased Fas-mediated apoptosis in human gastric carcinoma cell lines. "
12/01/2001 - "The effects of NS-398, a selective COX-2 inhibitor, on human prostate carcinoma cell line LNCaP and the LNCaP subline C4-2b were investigated in this study. "
06/01/2013 - "Together, our results suggest that NS-398 could be useful in prevention and therapy of ovarian carcinoma."
02/01/2011 - "After the treatment with NS-398 on esophageal carcinoma EC9706 cell, MTT assay was used to observe the inhibition of EC9706 cell growth and apoptosis was determined by electronic microscopy and flow cytometry. "
04/01/2008 - "To investigate the regulative effect of the nonsteroidal anti-inflammatory drug NS398 on the RECK gene in the prostate carcinoma strain DU145. "
|4.||Colonic Neoplasms (Colon Cancer)
08/01/2010 - "Human colon cancer cells SW480 were divided into two groups: SW480 cells in experimental group were treated with NS398 in different concentrations(25 micromol/L, 50 micromol/L, 100 micromol/L and 200 micromol/L) for 48 h or 72 h. "
04/28/2006 - "In addition, pretreatment with NS-398 to inhibit COX-2 activity also effectively suppressed DFX-induced HIF-1alpha accumulation in human colon cancer cells, providing the evidence that COX-2 plays as a regulator of HIF-1alpha accumulation in DFX-treated colon cancer cells. "
09/21/2005 - "COX-2 inhibitor, such as NS-398 inhibits the colon cancer cell proliferation and induces apoptosis of colon cancer cells with the possible mechanism of inhibiting the proliferation and inducing the apoptosis of colon cancer cells through a pathway independent of COX-2."
01/21/2005 - "NS-398 has anti-invasive effects on colon cancer HT-29 cells in vitro, which may be mediated by a novel mechanism of disruption of cytoskeleton. "
01/21/2005 - "Effect of NS-398 on colon cancer cells."
|5.||Hepatocellular Carcinoma (Hepatoma)
05/01/2001 - "In addition, we evaluated the efficacy of a selective COX-2 inhibitor, NS-398, in three hepatoma cell lines. "
04/01/2003 - "The present study assessed the effects of a selective COX-2 inhibitor, NS-398, on proliferation of human hepatoma cells in association with COX-2 expression, and the possible mechanisms. "
09/01/2008 - "Survivin was down-regulated in the growth inhibition of hepatoma cells induced by a selective COX-2 inhibitor, NS-398, in a concentration- and time-dependent manner. "
09/01/2008 - "NS-398 inhibited the growth of hepatoma cells by an amount dependent on the concentration and the time since treatment. "
02/28/2007 - "Selective COX-2 inhibitor, NS-398, suppresses cellular proliferation in human hepatocellular carcinoma cell lines via cell cycle arrest."
|1.||Cyclooxygenase 2 (Cyclooxygenase-2)
|4.||Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
|5.||N- (2- cyclohexyloxy- 4- nitrophenyl)methanesulfonamide
|6.||Aspirin (Acetylsalicylic Acid)
|7.||Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)
|5.||Surgical Instruments (Clip)